What Is CJC-1295 (No DAC)? A Guide to CJC-1295 Peptide Research
CJC-1295 Peptide is a synthetic peptide studied in endocrine and growth hormone signalling research. Interest in CJC-1295 No DAC, often associated with the name MOD GRF 1-29, centres on its relationship with growth hormone-releasing hormone (GHRH) and the mechanisms involved in peptide-receptor signalling.
For researchers exploring research peptides UK, understanding the terminology and the distinction between different forms of CJC-1295 is particularly important.
What Is CJC-1295 Peptide?
CJC-1295 belongs to a group of synthetic compounds designed around growth hormone-releasing hormone (GHRH). GHRH is involved in signalling the pituitary gland and regulating growth hormone secretion.
Published human research on long-acting CJC-1295 demonstrates why this pathway has received scientific attention. In two randomised, placebo-controlled trials involving healthy adults aged 21–61, researchers reported that a single dose of long-acting CJC-1295 increased mean growth hormone concentrations approximately 2–10-fold and IGF-I concentrations 1.5–3-fold under the study conditions.
Importantly, those results concern the long-acting CJC-1295 studied in that trial and should not be treated as evidence for commercially labelled CJC-1295 No DAC/MOD GRF 1-29 products.
What Does CJC-1295 No DAC Mean?
The terms CJC-1295 DAC and CJC-1295 No DAC are commonly encountered when researching this peptide.
DAC refers to a Drug Affinity Complex, developed to extend the activity of CJC-1295 through albumin binding. Published research from National Library of Medicine describes long-acting CJC-1295 as having an estimated half-life of approximately 5.8–8.1 days.
By contrast, products marketed as CJC-1295 (No DAC) are generally associated with MOD GRF 1-29 and are studied as shorter-acting GHRH analogues. Researchers should therefore avoid assuming that findings from long-acting CJC-1295 with DAC apply directly to CJC-1295 No DAC.
Why Is CJC-1295 Studied?
Scientific interest in CJC-1295 research and related GHRH analogues includes areas such as:
- Growth hormone signalling pathways
- GHRH receptor interactions
- Endocrine research models
- Peptide stability and molecular behaviour
- Pulsatile hormone signalling
Another human study of long-acting CJC-1295 found that growth hormone pulsatility was preserved while mean GH increased by 46% and IGF-I by 45% under the study conditions. Researchers can read the underlying studies through PubMed.
Why Does Peptide Quality Matter?
For laboratory research, accurate identification, purity and batch consistency are important. Researchers sourcing CJC-1295 peptide or other UK peptides should look for transparent analytical documentation rather than relying solely on product claims.
Supreme Peptides supplies CJC-1295 (No DAC) 2mg for scientific research. Researchers can review available third-party testing through the Supreme Peptides Lab Reports and explore the research peptide range.
As research into CJC-1295, MOD GRF 1-29 and GHRH peptides develops, distinguishing between peptide variants and interpreting studies in their proper context remain essential.
Important: Supreme Peptides products are supplied exclusively for scientific and laboratory research and are not intended for human or veterinary consumption, administration, diagnosis, treatment or therapeutic use.